BioSpace News Archive

After a few close friends were diagnosed with cancer, Templeton Apus was alerted to the fact that there was no in-depth service specifically designed to keep cancer patients on top of cancer updates and treatments worldwide. The launch of its Cancer Stat global news service has changed that.

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCyte’s Flow Electroporation® technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic

Can-Fite BioPharma Ltd. (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO Pnina Fishman Ph.D. will share insight into the Company’s recent developments during an investor webinar on Monday, November 25, 2019

NEW HAVEN, Conn., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie Smaldone Alsup, M.D., has joined its board of directors. Dr. Smaldone Alsup, who is currently the Chief Scientific Officer and Chief Medical Officer for NDA Group, brings experience leading commercially successful product approvals and global regulatory strategies that have advanced programs th

While most service members have experienced symptoms, only 53 percent have sought professional counseling

Cyxone announced that the company has signed an agreement with a UK contract research organization to conduct the six-month toxicology studies with Rabeximod as required ahead of the Phase IIb study.

Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company’s ImmTOR™ platform

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on ALT-801, the Company’s GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH), on Thursday, December 5th at 11am Eastern Time

Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developer of antibodies for cancer immune-therapy, today reported its financial results for the third quarter ended September 30, 2019

People living with type 2 diabetes can now have on-demand access to specialists and a robust network of endocrinologists directly from their phones